The Multiple Myeloma Therapy Market is becoming increasingly important within the oncology sector as advances in biotechnology create new ways to manage multiple myeloma. WiseGuyReports values the market at around USD 37.4 billion in 2024 and USD 39.8 billion in 2025, with the industry forecast to reach USD 75.0 billion by 2035 at a 6.5% CAGR from 2026 to 2035.

The competitive treatment landscape includes chemotherapy, targeted therapy, immunotherapy, and stem cell transplantation. While chemotherapy remains an established treatment option, targeted and immune-based therapies are gaining greater attention because of advances in understanding the molecular characteristics of multiple myeloma. Targeted therapy alone is projected to double from USD 15.0 billion in 2024 to USD 30.0 billion by 2035.

Another important market dimension is treatment stage. Patients may require different approaches during initial treatment, relapse, and maintenance therapy, creating continuing demand for new and complementary medicines. Oral, intravenous, and subcutaneous delivery methods provide additional flexibility, while the growing use of personalized treatment strategies is encouraging companies to develop therapies tailored to specific patient and disease characteristics.

North America remains a major center for multiple myeloma treatment and research. The regional market was approximately USD 17.2 billion in 2024 and is expected to reach USD 32.5 billion by 2035. Europe also maintains strong demand, while Asia Pacific is expected to benefit from improvements in healthcare infrastructure, increasing disease awareness, and expanding access to advanced oncology medicines.

Emerging opportunities are centered on CAR-T cell therapy, monoclonal antibodies, BCMA-targeted treatments, and innovative drug combinations. Pharmaceutical and biotechnology partnerships are supporting the development and commercialization of next-generation therapies, while manufacturing investments are helping expand access to advanced treatments. Continued innovation in personalized medicine is expected to remain a major influence on the market through 2035.